Stability of antiretroviral regimens in patients with viral suppression

AIDS

Volumn 22, Issue 9, 2008, Pages 1039-1046

  Lodwick, Rebecca K ^a   Smith, Colette J ^a   Youle, Mike ^b   Lampe, Fiona C ^a   Tyrer, Mervyn ^b   Bhagani, Sanjay ^b   Chaloner, Clinton ^a   Sabin, Caroline A ^a   Johnson, Margaret A ^b   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Discontinuation; HIV AIDS; Modification; Tolerability

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ALLERGIC REACTION; ANEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSOMNIA; KIDNEY DISEASE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIVARIATE ANALYSIS; MYOSITIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SIDE EFFECT; TIME SERIES ANALYSIS; VIROLOGY; VIRUS INFECTION; VOMITING;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LONDON; MALE; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 44449142338     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fec415     Document Type: Article

References (23)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Monforte AD, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
2. Ahdieh-Grant L, Tarwater PM, Schneider ME, Anastos K, Cohen M, Khalsa A, et al. Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the women's interagency HIV study. JAIDS 2005; 38:500-503.
3. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003; 37:714-722.
4. Hansel A, Bucher HC, Nuesch R, Battegay H. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. JAIDS 2001; 26:191-193.
5. Hooshyar D, Napravnik S, Miller WC, Eron JJ. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. AIDS 2006; 20:575-583.
6. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Lepri AC, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185-194.
7. Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, et al. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005; 10:779-790.
8. Monforte AD, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000; 14:499-507.
9. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. JAIDS 2003; 34:407-414.
10. Spire B, Carrieri P, Garzot MA, L'Henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004; 16:558-564.
11. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts ACG. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. JAIDS 1999; 20:290-294.
12. Yuan Y, L'Italien G, Mukherjee J, Iloeje UH. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7:156-162.
13. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. Aids Res Hum Retroviruses 2005; 21:743-752.
14. Li XH, Margolick JB, Conover CS, Badri S, Riddler SA, Witt MD, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. JAIDS 2005; 38:320-328.
15. Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, et al. The rate of viral rebound after attainment of an HIV load <50 copies/ml according to specific antiretroviral drugs in use: results from a multicenter cohort study. J Infect Dis 2005; 192:1387-1397.
16. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy - A multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166:521-528.
17. Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, et al. Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS 2007; 21:1423-1430.
18. Sungkanuparph S, Groger RK, Overton T, Fraser VJ, Powderly WG. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7:437-441.
19. Sabin CA, Lampe FC, Chaloner C, Madge SJ, Lipman MCI, Youle M, et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med 2003; 4:87-93.
20. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, Gibb DM, et al. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther 2006; 11:741-749.
21. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10:615-624.
22. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
23. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, Monforte AD, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.